Aplastic anemia in adults - Symptoms, Causes, Images, and Treatment Options

Diseases

Highlights & Basics

Key Highlights

Aplastic anemia is a form of pancytopenia; it is most often idiopathic in etiology.
Patients may present with sequelae of neutropenia (infections), anemia (fatigue, pallor, dyspnea, tachycardia), or thrombocytopenia (bleeding, bruising).
Laboratory findings may include leukopenia, neutropenia, anemia, and thrombocytopenia. Bone marrow biopsy shows hypocellular marrow with no abnormal cells, infiltrates or fibrosis.
Treatment includes immunosuppressive therapy with or without eltrombopag, or allogeneic stem cell transplantation.

Quick Reference

History & Exam
- Key Factors
- Other Factors
More information...
Diagnostics Tests
More information...
Treatment Options
More information...

Definition

Epidemiology

Etiology

Pathophysiology

Citations

Key Articles

Kulasekararaj A, Cavenagh J, Dokal I, et al. Guidelines for the diagnosis and management of adult aplastic anaemia: a British Society for Haematology Guideline. Br J Haematol. 2024 Mar;204(3):784-804.[Abstract][Full Text]
Townsley DM, Dumitriu B, Young NS. Bone marrow failure and the telomeropathies. Blood. 2014 Oct 30;124(18):2775-83.[Abstract][Full Text]

Other Online Resources

Aplastic Anemia & MDS International Foundation

Referenced Articles

1. Kulasekararaj A, Cavenagh J, Dokal I, et al. Guidelines for the diagnosis and management of adult aplastic anaemia: a British Society for Haematology Guideline. Br J Haematol. 2024 Mar;204(3):784-804.[Abstract][Full Text]
2. Furlong E, Carter T. Aplastic anaemia: current concepts in diagnosis and management. J Paediatr Child Health. 2020 Jul;56(7):1023-8.[Abstract]
3. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006 Oct 15;108(8):2509-19.[Abstract][Full Text]
4. Young NS. Acquired aplastic anemia. Ann Intern Med. 2002 Apr 2;136(7):534-46.[Abstract]
5. Gonnot M, Neumann F, Huet F, et al. Hepatitis-associated aplastic anemia. J Pediatr Gastroenterol Nutr. 2022 Nov 1;75(5):553-5.[Abstract]
6. Jaime-Pérez JC, González-Treviño M, Gómez-Almaguer D. Pregnancy-associated aplastic anemia: a case-based review. Expert Rev Hematol. 2021 Feb;14(2):175-84.[Abstract]
7. Moreno OM, Paredes AC, Suarez-Obando F, et al. An update on fanconi anemia: clinical, cytogenetic and molecular approaches (review). Biomed Rep. 2021 Sep;15(3):74.[Abstract][Full Text]
8. Townsley DM, Dumitriu B, Young NS. Bone marrow failure and the telomeropathies. Blood. 2014 Oct 30;124(18):2775-83.[Abstract][Full Text]
9. Ruggero D, Shimamura A. Marrow failure: a window into ribosome biology. Blood. 2014 Oct 30;124(18):2784-92.[Abstract][Full Text]
10. Spinner MA, Sanchez LA, Hsu AP, et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood. 2014 Feb 6;123(6):809-21.[Abstract][Full Text]
11. Dickinson RE, Milne P, Jardine L, et al. The evolution of cellular deficiency in GATA2 mutation. Blood. 2014 Feb 6;123(6):863-74.[Abstract][Full Text]
12. International Agranulocytosis and Aplastic Anemia Study Group. Incidence of aplastic anemia: the relevance of diagnostic criteria. Blood. 1987 Dec;70(6):1718-21.[Abstract]
13. Vaht K, Göransson M, Carlson K, et al. Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000-2011. Haematologica. 2017 Oct;102(10):1683-90.[Abstract][Full Text]
14. Montané E, Ibáñez L, Vidal X, et al. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica. 2008 Apr;93(4):518-23.[Abstract][Full Text]
15. Vallejo C, Rosell A, Xicoy B, et al. A multicentre ambispective observational study into the incidence and clinical management of aplastic anaemia in Spain (IMAS study). Ann Hematol. 2024 Mar;103(3):705-13.[Abstract]
16. Young NS, Kaufman DW. The epidemiology of acquired aplastic anemia. Haematologica. 2008 Apr;93(4):489-92.[Abstract][Full Text]
17. Norasetthada L, Wongkhantee S, Chaipokam J, et al. Adult aplastic anemia in Thailand: incidence and treatment outcome from a prospective nationwide population-based study. Ann Hematol. 2021 Oct;100(10):2443-52.[Abstract][Full Text]
18. Li SS, Hsu YT, Chang C, et al. Incidence and treatment outcome of aplastic anemia in Taiwan-real-world data from single-institute experience and a nationwide population-based database. Ann Hematol. 2019 Jan;98(1):29-39.[Abstract]
19. Kojima S. Why is the incidence of aplastic anemia higher in Asia? Expert Rev Hematol. 2017 Apr;10(4):277-9.[Abstract][Full Text]
20. Liang J, Yagasaki H, Kamachi Y, et al. Mutations in telomerase catalytic protein in Japanese children with aplastic anemia. Haematologica. 2006 May;91(5):656-8.[Abstract][Full Text]
21. Marsh JCW, Gutierrez-Rodrigues F, Cooper J, et al. Heterozygous RTEL1 variants in bone marrow failure and myeloid neoplasms. Blood Adv. 2018 Jan 4;2(1):36-48.[Abstract][Full Text]
22. Cardoso SR, Ellison ACM, Walne AJ, et al. Myelodysplasia and liver disease extend the spectrum of RTEL1 related telomeropathies. Haematologica. 2017 Aug;102(8):e293-6.[Abstract][Full Text]
23. Bluteau O, Sebert M, Leblanc T, et al. A landscape of germ line mutations in a cohort of inherited bone marrow failure patients. Blood. 2018 Feb 15;131(7):717-32.[Abstract]
24. Dufour C. How I manage patients with Fanconi anaemia. Br J Haematol. 2017 Jul;178(1):32-47.[Abstract]
25. Park M. Overview of inherited bone marrow failure syndromes. Blood Res. 2022 Apr 30;57(s1):49-54.[Abstract][Full Text]
26. Avenoso D, Marsh JCW, Potter V, et al. SARS-CoV-2 infection in aplastic anemia. Haematologica. 2022 Feb 1;107(2):541-3.[Abstract][Full Text]
27. DeZern AE, Churpek JE. Approach to the diagnosis of aplastic anemia. Blood Adv. 2021 Jun 22;5(12):2660-71.[Abstract][Full Text]
28. Niraj J, Färkkilä A, D'Andrea AD. The fanconi anemia pathway in cancer. Annu Rev Cancer Biol. 2019 Mar;3:457-78.[Abstract][Full Text]
29. Tummala H, Walne A, Dokal I. The biology and management of dyskeratosis congenita and related disorders of telomeres. Expert Rev Hematol. 2022 Aug;15(8):685-96.[Abstract][Full Text]
30. Nelson AS, Myers KC. Diagnosis, treatment, and molecular pathology of Shwachman-Diamond syndrome. Hematol Oncol Clin North Am. 2018 Aug;32(4):687-700.[Abstract]
31. Ganapathi KA, Townsley DM, Hsu AP, et al. GATA2 deficiency-associated bone marrow disorder differs from idiopathic aplastic anemia. Blood. 2015 Jan 1;125(1):56-70.[Abstract][Full Text]
32. Kordasti S, Marsh J, Al-Khan S, et al. Functional characterization of CD4+ T cells in aplastic anemia. Blood. 2012 Mar 1;119(9):2033-43. [Abstract][Full Text]
33. Solomou EE, Rezvani K, Mielke S, et al. Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. Blood. 2007 Sep 1;110(5):1603-6. [Abstract][Full Text]
34. de Latour RP, Visconte V, Takaku T, et al. Th17 immune responses contribute to the pathophysiology of aplastic anemia. Blood. 2010 Nov 18;116(20):4175-84. [Abstract][Full Text]
35. Shi J, Ge M, Lu S, et al. Intrinsic impairment of CD4(+)CD25(+) regulatory T cells in acquired aplastic anemia. Blood. 2012 Aug 23;120(8):1624-32.[Abstract][Full Text]
36. Kordasti S, Costantini B, Seidl T, et al. Deep phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment. Blood. 2016 Sep 1;128(9):1193-205. [Abstract][Full Text]
37. Giudice V, Selleri C. Aplastic anemia: pathophysiology. Semin Hematol. 2022 Jan;59(1):13-20.[Abstract]
38. Shimamura A. Inherited bone marrow failure syndromes: molecular features. Hematology Am Soc Hematol Educ Program. 2006:63-71.[Abstract][Full Text]
39. Calado RT, Young NS. Telomere diseases. N Engl J Med. 2009 Dec 10;361(24):2353-65.[Abstract][Full Text]
40. Locasciulli A, Bacigalupo A, Bruno B, et al. Hepatitis-associated aplastic anaemia: epidemiology and treatment results obtained in Europe. A report of The EBMT aplastic anaemia working party. Br J Haematol. 2010 Jun;149(6):890-5.[Abstract]
41. Anderson E, Shah B, Davidson A, et al. Lessons learned from bone marrow failure in systemic lupus erythematosus: case reports and review of the literature. Semin Arthritis Rheum. 2018 Aug;48(1):90-104.[Abstract][Full Text]
42. Gendron N, de Fontbrune FS, Guyard A, et al. Aplastic anemia related to thymoma: a survey on behalf of the French reference center of aplastic anemia and a review of the literature. Haematologica. 2020 Jul;105(7):e333-6.[Abstract][Full Text]
43. Antic M, Lautenschlager S, Itin PH. Eosinophilic fasciitis 30 years after - what do we really know? Report of 11 patients and review of the literature. Dermatology. 2006;213(2):93-101.[Abstract]
44. Salmeron G, Patey N, de Latour RP, et al. Coeliac disease and aplastic anaemia: a specific entity? Br J Haematol. 2009 Jun;146(1):122-4.[Full Text]
45. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15;140(11):1200-28.[Abstract][Full Text]
46. Barrett J, Saunthararajah Y, Molldrem J. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol. 2000 Jan;37(1):15-29.[Abstract]
47. Bono E, McLornan D, Travaglino E, et al. Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome. Leukemia. 2019 Oct;33(10):2495-505.[Abstract][Full Text]
48. Babushok DV, DeZern AE, de Castro CM, et al. Modified Delphi panel consensus recommendations for management of severe aplastic anemia. Blood Adv. 2024 Aug 13;8(15):3946-60.[Abstract][Full Text]
49. Li J, Li X, Cai L, et al. Prognostic value of pre-treatment PNH clone among the patients with aplastic anemia: a meta-analysis. Hematology. 2023 Dec;28(1):2204617.[Abstract][Full Text]
50. Klingemann HG, Storb R, Sanders J, et al. Acute lymphoblastic leukaemia after bone marrow transplantation for aplastic anaemia. Br J Haematol. 1986 May;63(1):47-50.[Abstract]
51. Camitta BM, Thomas ED, Nathan DG, et al. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood. 1976 Jul;48(1):63-70.[Abstract][Full Text]
52. Bacigalupo A, Hows J, Gluckman E, et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party. Br J Haematol. 1988 Oct;70(2):177-82.[Abstract]
53. Fattizzo B, Gurnari C, Cassanello G, et al. Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study. Leukemia. 2023 Dec;37(12):2479-85.[Abstract][Full Text]
54. Calado RT, Clé DV. Treatment of inherited bone marrow failure syndromes beyond transplantation. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):96-101.[Abstract][Full Text]
55. Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood. 1999 Apr 1;93(7):2191-5.[Abstract][Full Text]
56. Frickhofen N, Rosenfeld SJ. Immunosuppressive treatment of aplastic anemia with antithymocyte globulin and cyclosporine. Semin Hematol. 2000 Jan;37(1):56-68.[Abstract]
57. Camitta BM. A controlled prospective trial of antithoracic duct lymphocyte globulin (ATDLG) for treatment of severe aplastic anemia. Prog Clin Biol Res. 1984;148:239-47.[Abstract]
58. Champlin R, Ho W, Gale RP. Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial. N Engl J Med. 1983 Jan 20;308(3):113-8.[Abstract]
59. Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med. 1991 May 9;324(19):1297-304.[Abstract][Full Text]
60. Rosenfeld S, Follmann D, Nuñez O, et al. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003 Mar 5;289(9):1130-5.[Abstract][Full Text]
61. Frickhofen N, Heimpel H, Kaltwasser JP, et al; German Aplastic Anemia Study Group. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003 Feb 15;101(4):1236-42.[Abstract][Full Text]
62. Fan X, Desmond R, Winkler T, et al. Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias. Blood Adv. 2020 Apr 28;4(8):1700-10.[Abstract][Full Text]
63. Bejanyan N, Kim S, Hebert KM, et al. Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Adv. 2019 Oct 22;3(20):3123-31.[Abstract][Full Text]
64. Peffault de Latour R, Kulasekararaj A, Iacobelli S, et al. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia. N Engl J Med. 2022 Jan 6;386(1):11-23.[Abstract]
65. Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017 Apr 20;376(16):1540-50. [Abstract][Full Text]
66. European Blood and Marrow Transplant Group, Severe Aplastic Anaemia Working Party. Rabbit ATG for aplastic anaemia treatment: a backward step? Lancet. 2011 Nov 26;378(9806):1831-3.[Abstract]
67. Scheinberg P, Finelli C, Montaňo-Figueroa EH, et al. Activity and safety of eltrombopag in combination with cyclosporin A as first‑line treatment of adults with severe aplastic anaemia (SOAR): a phase 2, single-arm study. Lancet Haematol. 2024 Mar;11(3):e206-15.[Abstract]
68. Bacigalupo A, Locatelli F, Lanino E, et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant. 2005 Dec;36(11):947-50.[Abstract]
69. Deeg HJ, O'Donnell M, Tolar J, et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood. 2006 Sep 1;108(5):1485-91.[Abstract][Full Text]
70. Iftikhar R, Chaudhry QUN, Anwer F, et al. Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies. Blood Rev. 2021 May;47:100772.[Abstract]
71. Marsh JC, Gupta V, Lim Z, et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft versus host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood. 2011 Aug 25;118(8):2351-7. [Abstract][Full Text]
72. Bacigalupo A, Socie G, Lanino E, et al; Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party. Haematologica. 2010 Jun;95(6):976-82.[Abstract][Full Text]
73. Eapen M. Allogeneic transplantation for aplastic anemia. Hematology. 2012 Apr;17(suppl 1):S15-7. [Abstract]
74. Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012 Jul 5;367(1):11-9.[Abstract][Full Text]
75. Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores tri-lineage hematopoiesis in refractory severe aplastic anemia which can be sustained on discontinuation of drug. Blood. 2014 Mar 20;123(12):1818-25.[Abstract]
76. Lengline E, Drenou B, Peterlin P, et al. Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. Haematologica. 2018 Feb;103(2):212-20.[Abstract][Full Text]
77. Marsh JC, Kulasekararaj AG. Management of the refractory aplastic anemia patient: what are the options? Blood. 2013 Nov 21;122(22):3561-7.[Abstract][Full Text]
78. Pagliuca S, Kulasekararaj AG, Eikema DJ, et al. Current use of androgens in bone marrow failure disorders: a report from the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2024 Mar 1;109(3):765-76.[Abstract][Full Text]
79. Jaime-Pérez JC, Colunga-Pedraza PR, Gómez-Ramírez CD, et al. Danazol as first-line therapy for aplastic anemia. Ann Hematol. 2011 May;90(5):523-7. [Abstract]
80. Townsley DM, Dumitriu B, Liu D, et al. Danazol treatment for telomere diseases. N Engl J Med. 2016 May 19;374(20):1922-31. [Abstract][Full Text]
81. Killick SB, Win N, Marsh JC, et al. Pilot study of HLA alloimmunization after transfusion with pre-storage leucodepleted blood products in aplastic anaemia. Br J Haematol. 1997 Jun;97(3):677-84. [Abstract]
82. Quillen K, Wong E, Scheinberg P, et al. Granulocyte transfusions in severe aplastic anemia: an eleven-year experience. Haematologica. 2009 Dec;94(12):1661-8.[Abstract][Full Text]
83. Shah FT, Porter JB, Sadasivam N, et al. Guidelines for the monitoring and management of iron overload in patients with haemoglobinopathies and rare anaemias. Br J Haematol. 2022 Jan;196(2):336-50.[Abstract][Full Text]
84. Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011 Aug 4;365(5):430-8. [Abstract][Full Text]
85. Marsh J, Socie G, Tichelli A, et al, on behalf of the EBMT Severe Aplastic Anaemia (SAA) Working Party. Prospective phase II pilot study of rabbit antithymocyte globulin with ciclosporin for patients with acquired aplastic anaemia and matched pair analysis with patients treated with horse ATG and ciclosporin. EBMT 2011 physicians' abstracts: no.208. Bone Marrow Transplant. 2011;46(Suppl 1):S30.[Full Text]
86. Afable MG 2nd, Shaik M, Sugimoto Y, et al. Efficacy of rabbit antithymocyte globulin in severe aplastic anemia. Haematologica. 2011 Sep;96(9):1269-75.[Abstract][Full Text]
87. Vaht K, Göransson M, Carlson K, et al. Low response rate to ATG-based immunosuppressive therapy in very severe aplastic anaemia - a Swedish nationwide cohort study. Eur J Haematol. 2018 Jun;100(6):613-20.[Abstract]
88. Peffault de Latour R, Tabrizi R, Marcais A, et al. Nationwide survey on the use of horse antithymocyte globulins (ATGAM) in patients with acquired aplastic anemia: a report on behalf of the French Reference Center for aplastic anemia. Am J Hematol. 2018 May;93(5):635-42.[Abstract][Full Text]
89. Scheinberg P, Rios O, Scheinberg P, et al. Prolonged cyclosporine administration after antithymocyte globulin delays but does not prevent relapse in severe aplastic anemia. Am J Hematol. 2014 Jun;89(6):571-4.[Abstract][Full Text]
90. Mao P, Zhu Z, Wang H, et al. Sustained and stable hematopoietic donor-recipient mixed chimerism after unrelated cord blood transplantation for adult patients with severe aplastic anemia. Eur J Haematol. 2005 Nov;75(5):430-5.[Abstract]
91. Ohga S, Ichino K, Goto K, et al. Unrelated donor cord blood transplantation for childhood severe aplastic anemia after a modified conditioning. Pediatr Transplant. 2006 Jun;10(4):497-500.[Abstract]
92. Motwani J, Lawson SE, Darbyshire PJ. Successful HSCT using nonradiotherapy-based conditioning regimens and alternative donors in patients with Fanconi anaemia - experience in a single UK centre. Bone Marrow Transplant. 2005 Sep;36(5):405-10.[Abstract]
93. Vibhakar R, Radhi M, Rumelhart S, et al. Successful unrelated umbilical cord blood transplantation in children with Shwachman-Diamond syndrome. Bone Marrow Transplant. 2005 Nov;36(10):855-61.[Abstract]
94. Childs RW, Tian X, Vo P, et al. Combined haploidentical and cord blood transplantation for refractory severe aplastic anaemia and hypoplastic myelodysplastic syndrome. Br J Haematol. 2021 Jun;193(5):951-60.[Abstract][Full Text]
95. McCurdy SR, Luznik L. How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide. Blood. 2019 Nov 21;134(21):1802-10.[Abstract][Full Text]
96. ElGohary G, El Fakih R, de Latour R, et al. Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP of EBMT). Bone Marrow Transplant. 2020 Oct;55(10):1906-17.[Abstract]
97. DeZern AE, Zahurak ML, Symons HJ, et al. Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Adv. 2020 Apr 28;4(8):1770-9.[Abstract][Full Text]
98. Prata PH, Eikema DJ, Afansyev B, et al. Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party. Bone Marrow Transplant. 2020 Jun;55(6):1050-8.[Abstract]
99. DeZern AE, Eapen M, Wu J, et al. Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2022 Sep;9(9):e660-9.[Abstract][Full Text]
100. DeZern AE, Zahurak M, Symons HJ, et al. Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia. Blood. 2023 Jun 22;141(25):3031-8.[Abstract][Full Text]
101. Montoro J, Eikema DJ, Tuffnell J, et al. Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT. Blood. 2024 Jul 18;144(3):323-3.[Abstract][Full Text]
102. Patel BJ, Barot SV, Kuzmanovic T, et al. Distinctive and common features of moderate aplastic anaemia. Br J Haematol. 2020 Jun;189(5):967-75.[Abstract][Full Text]
103. Nakamura R, Patel BA, Kim S, et al. Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy. Haematologica. 2023 Dec 1;108(12):3298-307.[Abstract][Full Text]
104. Bacigalupo A, Socié G, Hamladji RM, et al. Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis. Haematologica. 2015 May;100(5):696-702. [Abstract][Full Text]
105. Grimaldi F, Potter V, Perez-Abellan P, et al. Mixed T cell chimerism after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia using an alemtuzumab-containing regimen is shaped by persistence of recipient CD8 T cells. Biol Blood Marrow Transplant. 2017 Feb;23(2):293-9. [Abstract][Full Text]
106. Alotaibi H, Aljurf M, de Latour R, et al. Upfront alternative donor transplant versus immunosuppressive therapy in patients with severe aplastic anemia who lack a fully HLA-matched related donor: systematic review and meta-analysis of retrospective studies, on behalf of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Transplant Cell Ther. 2022 Feb;28(2):105.e1-7.[Abstract][Full Text]
107. Valdez JM, Scheinberg P, Nunez O, et al. Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades. Clin Infect Dis. 2011 Mar 15;52(6):726-35.[Abstract]
108. Socié G, Rosenfeld S, Frickhofen N, et al. Late clonal diseases of treated aplastic anemia. Semin Hematol. 2000 Jan;37(1):91-101.[Abstract]
109. Kulasekararaj AG, Jiang J, Smith AE, et al. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood. 2014 Oct 23;124(17):2698-704.[Abstract][Full Text]
110. Socié G, Henry-Amar M, Bacigalupo A, et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med. 1993 Oct 14;329(16):1152-7.[Abstract][Full Text]
111. Armand P, Antin JH. Allogeneic stem cell transplantation for aplastic anemia. Biol Blood Marrow Transplant. 2007 May;13(5):505-16.[Abstract][Full Text]
112. Young NS. Aplastic Anemia. N Engl J Med. 2018 Oct 25;379(17):1643-56.[Full Text]
113. Piekarska A, Pawelec K, Szmigielska-Kapłon A, et al. The state of the art in the treatment of severe aplastic anemia: immunotherapy and hematopoietic cell transplantation in children and adults. Front Immunol. 2024;15:1378432.[Abstract][Full Text]
114. Sanders JE, Woolfrey AE, Carpenter PA, et al. Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia. Blood. 2011 Aug 4;118(5):1421-8.[Abstract][Full Text]
115. Eapen M, Ramsay NK, Mertens AC, et al. Late outcomes after bone marrow transplant for aplastic anaemia. Br J Haematol. 2000 Dec;111(3):754-60.[Abstract]
116. Deeg HJ, Socié G, Schoch G, et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood. 1996 Jan 1;87(1):386-92.[Abstract][Full Text]
117. Marsh JC, Zomas A, Hows JM, et al. Avascular necrosis after treatment of aplastic anaemia with antilymphocyte globulin and high-dose methylprednisolone. Br J Haematol. 1993 Aug;84(4):731-5.[Abstract]